| Product Code: ETC9556037 | Publication Date: Sep 2024 | Updated Date: Sep 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Dhaval Chaurasia | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Sweden Glucagon like Peptide 1 (GLP 1) Agonists Market Overview |
3.1 Sweden Country Macro Economic Indicators |
3.2 Sweden Glucagon like Peptide 1 (GLP 1) Agonists Market Revenues & Volume, 2021 & 2031F |
3.3 Sweden Glucagon like Peptide 1 (GLP 1) Agonists Market - Industry Life Cycle |
3.4 Sweden Glucagon like Peptide 1 (GLP 1) Agonists Market - Porter's Five Forces |
3.5 Sweden Glucagon like Peptide 1 (GLP 1) Agonists Market Revenues & Volume Share, By Drugs, 2021 & 2031F |
3.6 Sweden Glucagon like Peptide 1 (GLP 1) Agonists Market Revenues & Volume Share, By Brands, 2021 & 2031F |
4 Sweden Glucagon like Peptide 1 (GLP 1) Agonists Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of diabetes in Sweden |
4.2.2 Growing awareness about the benefits of GLP-1 agonists in managing diabetes |
4.2.3 Technological advancements leading to the development of more effective GLP-1 agonists |
4.3 Market Restraints |
4.3.1 Stringent regulatory requirements for approval of new GLP-1 agonists in Sweden |
4.3.2 High cost associated with GLP-1 agonist therapies |
4.3.3 Limited reimbursement policies for GLP-1 agonists in the Swedish healthcare system |
5 Sweden Glucagon like Peptide 1 (GLP 1) Agonists Market Trends |
6 Sweden Glucagon like Peptide 1 (GLP 1) Agonists Market, By Types |
6.1 Sweden Glucagon like Peptide 1 (GLP 1) Agonists Market, By Drugs |
6.1.1 Overview and Analysis |
6.1.2 Sweden Glucagon like Peptide 1 (GLP 1) Agonists Market Revenues & Volume, By Drugs, 2021- 2031F |
6.1.3 Sweden Glucagon like Peptide 1 (GLP 1) Agonists Market Revenues & Volume, By Dulaglutide, 2021- 2031F |
6.1.4 Sweden Glucagon like Peptide 1 (GLP 1) Agonists Market Revenues & Volume, By Exenatide, 2021- 2031F |
6.1.5 Sweden Glucagon like Peptide 1 (GLP 1) Agonists Market Revenues & Volume, By Liraglutide, 2021- 2031F |
6.1.6 Sweden Glucagon like Peptide 1 (GLP 1) Agonists Market Revenues & Volume, By Lixisenatide, 2021- 2031F |
6.1.7 Sweden Glucagon like Peptide 1 (GLP 1) Agonists Market Revenues & Volume, By Semaglutide, 2021- 2031F |
6.2 Sweden Glucagon like Peptide 1 (GLP 1) Agonists Market, By Brands |
6.2.1 Overview and Analysis |
6.2.2 Sweden Glucagon like Peptide 1 (GLP 1) Agonists Market Revenues & Volume, By Byetta, 2021- 2031F |
6.2.3 Sweden Glucagon like Peptide 1 (GLP 1) Agonists Market Revenues & Volume, By Bydureon, 2021- 2031F |
6.2.4 Sweden Glucagon like Peptide 1 (GLP 1) Agonists Market Revenues & Volume, By Victoza, 2021- 2031F |
6.2.5 Sweden Glucagon like Peptide 1 (GLP 1) Agonists Market Revenues & Volume, By Trulicity, 2021- 2031F |
6.2.6 Sweden Glucagon like Peptide 1 (GLP 1) Agonists Market Revenues & Volume, By Lyxumia, 2021- 2031F |
6.2.7 Sweden Glucagon like Peptide 1 (GLP 1) Agonists Market Revenues & Volume, By Ozempic, 2021- 2031F |
7 Sweden Glucagon like Peptide 1 (GLP 1) Agonists Market Import-Export Trade Statistics |
7.1 Sweden Glucagon like Peptide 1 (GLP 1) Agonists Market Export to Major Countries |
7.2 Sweden Glucagon like Peptide 1 (GLP 1) Agonists Market Imports from Major Countries |
8 Sweden Glucagon like Peptide 1 (GLP 1) Agonists Market Key Performance Indicators |
8.1 Patient adherence rate to GLP-1 agonist therapy |
8.2 Number of clinical trials evaluating the efficacy of new GLP-1 agonists |
8.3 Prescription rates of GLP-1 agonists compared to other diabetes treatments |
9 Sweden Glucagon like Peptide 1 (GLP 1) Agonists Market - Opportunity Assessment |
9.1 Sweden Glucagon like Peptide 1 (GLP 1) Agonists Market Opportunity Assessment, By Drugs, 2021 & 2031F |
9.2 Sweden Glucagon like Peptide 1 (GLP 1) Agonists Market Opportunity Assessment, By Brands, 2021 & 2031F |
10 Sweden Glucagon like Peptide 1 (GLP 1) Agonists Market - Competitive Landscape |
10.1 Sweden Glucagon like Peptide 1 (GLP 1) Agonists Market Revenue Share, By Companies, 2024 |
10.2 Sweden Glucagon like Peptide 1 (GLP 1) Agonists Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here